Pendal Group’s BeOne Medicines Ltd ONC Stock Holding History

Pendal Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-23,728	Closed	-$6.8M	–	564
2020 Q3	$6.8M	Buy	+23,728	New	+$5.58M	0.08%	89

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pendal Group's ONC Position: Q4 2020 in Review

Pendal Group sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 23,728 shares — an estimated $6.8M sold.

Pendal Group first reported a position in ONC in Q3 2020 and held it in 1 quarter. The position peaked at $6.8M in Q3 2020. 247 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

Pendal Group reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
Pendal Group sold 23,728 BeOne Medicines Ltd shares in Q4 2020, an estimated $6.8M.
Pendal Group first reported a position in BeOne Medicines Ltd in Q3 2020 and held it in 1 quarter.
Pendal Group's BeOne Medicines Ltd position peaked at $6.8M in Q3 2020.
247 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Pendal Group's 13F filing for Q4 2020, filed 21 Jan 2021.